1. Gregson N, Sparrowhawk K, Mauskopf J, Paul J. Pricing medicines: theory and practice, challenges and opportunities. Nature Reviews | Drug Discovery 2005; 4:121-30.
   Summary
2. Use of pharmacoeconomics in prescribing research. Part 1: costs--moving beyond the acquisition price for drugs. (eng; includes abstract) By Robertson J, Journal Of Clinical Pharmacy And Therapeutics [J Clin Pharm Ther], 2003 Feb; Vol. 28 (1), pp. 73-9; PMID: 12605622

1. Gold MR, Siegel JE, Russell LB, Weinstein MC. Estimating Costs in Cost-Effectiveness Analysis. Cost-Effectiveness in Health and Medicine. New York: Oxford University Press, 1996.
   Review
2. Brouwer W, Rutten F, Koopmanschap M. Costing in Economic Evaluations. In: Drummond M, McGuire A. Economic Evaluations in Health Care: Merging Theory with Practice. New York: Oxford University Press, 2001.
   Review
3. Jacobs P, Ohinmaa A, Brady B. Providing Systemic Guidance in Pharmacoeconomic Guidelines for Analysing Costs. Pharmacoeconomics 2005; 23(2):143-53.
   http://www.ingentaconnect.com/content/adis/pec/2005/00000023/00000002/art00006
   PMID: 15748089 [PubMed - indexed for MEDLINE]
   Summary

1. Gilks WR, Spiegelhalter DJ, Richardson S (Eds.). Markov Chain Monte Carlo in Practice. Boca Raton, FL: Chapman & Hall; 1995.
    
2. Vanness DJ, Kim WR.  Bayesian Estimation, Simulation and Uncertainty Analysis: The Cost-Effectiveness of Ganciclovir Prophylaxis in Liver Transplantation. Health Econ. Sep;11(6):551-66, 2002.
   PMID: 12203757 [PubMed - indexed for MEDLINE]
   Review
    
3. Gordois A, Scuffham P, Shearer A, Oglesby A, Tobian JA. The health care costs of diabetic peripheral neuropathy in the US. Diabetes Care. Jun;26(6):1790-5, 2003.
   PMID: 15019595 [PubMed - indexed for MEDLINE]
   Summary
    
4. Shearer A, Scuffham P, Gordois A, Oglesby A. Predicted costs and outcomes from reduced vibration detection in people with diabetes in the U.S. Diabetes Care. Aug;26(8):2305-10, 2003.
   PMID: 12882853 [PubMed - indexed for MEDLINE]
   Summary
    
5. Gilmer TP, O'Connor PJ, Rush WA, Crain AL, Whitebird RR, Hanson AM, Solberg LI. Predictors of health care costs in adults with diabetes. Diabetes Care. Jan;28(1):59-64, 2005.
   PMID: 15616234 [PubMed - indexed for MEDLINE]
   Summary
    
6. Sidorov J, Shull R, Tomcavage J, Girolami S, Lawton N, Harris R.  Does Diabetes Disease Management Save Money and Improve Outcomes? A Report of Simultaneous Short-Term Savings and Quality Improvement Associated with a Health Maintenance Organization-Sponsored Disease Management Program Among Patients Fulfilling Health Employer Data and Information Set Criteria. Diabetes Care 2002;25(4):684-9.
   PMID: 11919125 [PubMed - indexed for MEDLINE]
   Summary
    
7. Vanness DJ, Kim WR. Modeling, Simulation and Uncertainty Analysis Using Markov Chain Monte Carlo: Glanciclovir Prophylaxis In Liver Transportation. Wisconsin Public Health and Health Policy Institute website. 2005. Available at:  http://www.pophealth.wisc.edu/UWPHI/education/seminars/vanness.pdf . Accessed July 7, 2005.
    
8. Redekop WK, Stolk EA, KOK E, Lovas K, Kalo Z, Busschbach JJ. Diabetic foot ulcers and amputations:estimates of health utility for use in cost-effectiveness analyses of new treatments. Diabetes Metab, 2004; 30(6):549-56
   PMID: 15671925 [PubMed - indexed for MEDLINE]
   Summary
    
9. Ramsey SD, Newton K, Blough D, McCulloch DK, Sandhu N, Reiber GE, Wagner EH. Incidence, Outcomes, and Cost of Foot Ulcers in Patients with Diabetes. Diabetes Care; 22:(3)382-387, 1999. 1999; 22:(3)382-387.
   PMID: 10097914 [PubMed - indexed for MEDLINE]
   Summary

1. Brouwer WB, Koopmanschap MA. The friction-cost method : Replacement for Nothing and Leisure for Free?  Pharmacoeconomics. 2005;23(2):105-11.
   PMID: 15748085 [PubMed - indexed for MEDLINE]
   Review
    
2. Liljas B. How to calculate indirect costs in economic evaluations. Pharmacoeconomics. 1998 Jan;13(1 Pt 1):1-7.
   Review
    
3. Koopmanschap MA, Rutten FF. A practical guide for calculating indirect costs of disease. Pharmacoeconomics. 1996 Nov;10(5):460-6.
   PMID: 10172868 [PubMed - indexed for MEDLINE]
   Review
    
4. Kobelt G. Health Economics: An Introduction to Economic Evaluation (2nd ed.). London: Office for Health Economics, 2002.
   Review

1. Hirth RA, Chernew ME, et al. Willingness to Pay for a Quality-Adjusted Life Year: In Search of a Standard. Medical Decision Making 2000;20(3):332-42.
   Review
    
2. ala MV, Mauskopf JA, Wood LL. “Willingness to pay as a measure of health benefits.” Pharmacoeconomics. Jan 1999;15(1):9-18.

1. Larson LN. Cost Determination and Analysis. Chapter 3 in: Bootman JL, Townsend RJ, McGhan WF. Principles of Pharmacoeconomics (3rd ed.). Cincinnati: Harvey Whitney Books Co., 2005.
   Review
    
2. Cost Analysis – Chapter 4 in: Drummond MF, Sculpher MJ, Torrance, O’Brian BJ, Stoddart GL. Methods for the Economic Evaluation of Health Care Programmes. Third Edition. Oxford, New York: Oxford University Press, 2005.
   Review

TOP